Background: Altered expression of a disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5) is observed in hepatocellular carcinoma. The genetic polymorphisms of this gene in aflatoxin B1 (AFB1)-related hepatocellular carcinoma have not yet been elucidated.
Introduction
Hepatocellular carcinoma, in addition to being the most common cancer worldwide in 2008, is the most common histopathologic type of liver cancer (1) . Approximately 50% all hepatocellular carcinoma cases and deaths were estimated to occur in the People's Republic of China (especially in the southeast areas such as Guangxi), mainly because of high aflatoxin B1 (AFB1) exposure and/or chronic infection of hepatitis B and C viruses (HBV and HCV, respectively; ref. 2) . Therefore, a better understanding of the molecular characteristics and underlying mechanism are of the utmost importance and may prove useful in developing novel strategies for the prevention, early detection, treatment, and prognosis of hepatocellular carcinoma. The hotspot mutation of the TP53 gene (TP53M) has been shown to be positively associated with AFB1 exposure levels and hepatocellular carcinoma risk factor (2, 3) . Until now, it has been regarded as an important biomarker of AFB1-related hepatocellular carcinoma as well as the serum AFB1 albumin adducts (AAA; refs. 2, 3). Recently, increasing evidence has shown potential associations of common genetic variants with AFB1-related hepatocellular carcinoma risk in biologically plausible pathways including DNA repair and detoxication pathways (4) . These genetic factors could feasibly be utilized as biomarkers of hepatocellular carcinoma induced by AFB1 exposure and prognostic indicators.
The disintegrin-like and metalloproteinase (ADAMTS) family member ADAMTS5 acts as a proteoglycanase and has been shown to be a major aggrecanase in cartilage destruction (5, 6) . Recently, a preponderance of evidence has implicated aberrant ADAMTS5 expression in the development and progression of some tumors including breast cancer, colorectal cancer, glioblastoma, hepatocellular carcinoma, and T-cell acute lymphoblastic leukemia (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . Despite the collected data, the association of altered ADAMTS5 expression and genetic variants of AFB1-related hepatocellular carcinoma remains to be elucidated. Here, we evaluated whether 74 SNPs in this gene modify AFB1-related hepatocellular carcinoma risk and prognosis.
Materials and Methods

Study subjects
We utilized a hospital-based case-control study of AFB1-related hepatocellular carcinoma in the Guangxi area according to a previously described protocol (19, 20) . Briefly, patients diagnosed with histopathologically confirmed hepatocellular carcinoma in hospitals affiliated with Guangxi Medical University and Youjiang Medical College for Nationalities in the Southwestern Guangxi from January 2004 to July 2014 were utilized. Individuals without clinical evidence of hepatic disease or tumors were recruited from the general health check-up center at the same hospitals during the same period for comparison. To control the effects of confounders, cases were individually matched (1:1 or 1:2) to controls based on gender, ethnicity (Han, Zhuang), age (AE5 years), and HBV and HCV infection. All controls were surveyed to ascertain their willingness to participate in the study and to provide preliminary demographic data. In this study, a total of 1,706 cases and 2,076 controls, representing 95% of eligible cases and 98% of eligible controls were interviewed and included the final analysis. From these subjects, 200 matched cases and controls were randomly selected for inclusion in the screening set, whereas the remainder was utilized for the validation group. Once informed, written consent was obtained for all participants and 4 mL of peripheral blood was collected along with demographic data. Surgically removed tumor samples and 207 fresh cancer tissue specimens were collected for ADAMTS5 expression analysis. All protocols were approved by the ethic committees of the participating hospitals and more detailed data collection can be found in the Supplementary Materials and Methods.
AFB1 exposure analysis
In this study, subject AFB1 exposure level was evaluated via the serum AAA levels using a comparative ELISA (21) . For statistical analysis, AAA values were logarithmically transformed and then were divided into three subgroups: low (<2.18 ln fmol/mg), medium (2.18-2.98 ln fmol/mg), and high (>2.98 ln fmol/mg), according to the mean logit value of serum AAA among controls and cases. These three subgroups represented low, medium, and high AFB1 exposure, respectively.
Mutation of TP53M at codon 249 of the TP53 gene was examined using the TaqMan-PCR methods (21) to assess the relationship between AFB1 exposure and hepatocellular carcinoma diagnosis. Briefly, Genomic DNA was isolated from cancerous tissues using FFPE DNA Kit (catalog # CW0547) by Cowin Biotech Co., Ltd. Each PCR was carried out in a total volume of 25 mL consisting of 1 Â Premix Ex Taq [catalog # DRR039A, TaKaRa Biotechnology (Dalian) Co., Ltd.], 0.2 mmol/L of each probe, 0.2 mmol/L of each primer, and 50 to 100 ng of genomic DNA. The PCR program had an initial denaturation step of 2 minutes at 95 C followed by 50 cycles of 10 seconds at 95 C and 1 minute at 60 C. For quality control, controls were included in each run, and repeated genotyping and sequencing of a random 10% subset yielded 100% identical genotypes. In this study, TP53M positive was defined as the TP53 genotypes with mutant codon 249 alleles.
ADAMTS5 SNP selection and analysis
Utilizing the application programming interface tools available from the ENSEMBL database, 1,143 SNPs in the ADAMTS5 gene were obtained. According to the criteria of minor allele frequency of more than 0.10 in Asians, 74 SNPs were selected for further analysis in the first stage of the study (Supplementary Table S1 ). Genotyping was performed by using the SNaPshot method. In the second stage of the study, four SNPs (rs2830581, rs162499, rs233895, and rs62215997) were further analyzed using the TaqMan-PCR method. More detailed information for SNPs selection and analysis is available in the Supplementary Materials and Methods.
ADAMTS5 expression analysis
ADAMTS5 expression levels were evaluated using both ADAMTS5 mRNA-expressing levels and protein-expressing levels. Detailed information about ADAMTS5 expression analysis is described in the Supplementary Materials and Methods.
Statistical analysis
We Kaplan-Meier survival analysis with the log-rank test was used to evaluate the effects of rs2830581 polymorphism on hepatocellular carcinoma prognosis. Risk factors for hepatocellular carcinoma prognosis were selected using the Cox multivariate regression model (including all possible multiplicatively interactive variables) with stepwise forward selection based on a likelihood ratio test. HRs and 95% CIs for risk factors were then calculated from a multivariate Cox regression model. All statistical analyses were carried out utilizing the SPSS version 18 (SPSS Institute).
Results
Characteristics of subjects
The distributions of demographic characteristics (including sex, age, race, and HBV and HCV status) between hepatocellular carcinoma cases and controls were not significantly different. However, hepatocellular carcinoma cases exhibited a higher level of AFB1-album adducts in the peripheral serum than controls (2.98 ). In the combined analysis utilizing all subjects (Merged set, Table 1 ), the adjusted OR for hepatocellular carcinoma among those heterozygous for rs2830581 G and A alleles (rs2830581-GA) versus those homozygous for rs2830581 G alleles (rs2830581-GG) was 1.85 (1.57-2.19). The corresponding OR for those homozygous for rs2830581 A alleles (rs2830581-AA) was 4.40 (3.43-5.64). Thus, hepatocellular carcinoma risk was associated with the number of rs2830581 A alleles.
To evaluate possible interactive effects of individually matching variables (including age, race, gender, HBV infection, and HCV infection) and ADAMTS5 rs2830581 polymorphism on hepatocellular carcinoma risk, the polymorphism analysis was stratified by matching factors. Results showed that these factors did not substantially modulate the effect of ADAMTS5 rs2830581 on cancer risk (P interaction > 0.05; Supplementary Table S5) .
Joint effects of ADAMTS5 rs2830581 polymorphism and AFB1 exposure on hepatocellular carcinoma risk
The joint effects of ADAMTS5 rs2830581 polymorphism and AFB1 exposure levels on hepatocellular carcinoma risk was carried out with the lowest risk group (those with rs2830581-GG and low level of AFB1 exposure) as a reference (Table 2 ). It was found that higher levels of AFB1 exposure consistently increased hepatocellular carcinoma risk; the risk was more pronounced among subjects with ADAMTS5 risk genotypes. There was evidence of multiplicatively interactive effects of genotypes and exposure levels on hepatocellular carcinoma risk [16. To determine more detailed interactive value, we conducted multiplicatively interactive analysis. In this analysis model, risk factors for hepatocellular carcinoma risk were selected using a multivariate logistic regression model (including all possible multiplicatively interactive variables) with stepwise forward selection based on a likelihood ratio test. Next, the OR interaction and 95% CIs for AFB1-genotype interactive variables were calculated in the same multivariate model (simultaneously including all risk variables and multiplicatively interactive variables). We found significantly interactive values [OR interaction (95% CI/P), 1.63 (1.08-2.46/0.02) for high AFB1 exposure level Â rs2830581-GA; 4.37 (1.76-10.86/1.48 Â 10 À3 ) for high AFB1
exposure level Â rs2830581-AA, respectively]. Together, the data indicated that AFB1 exposure multiplicatively interacted with ADAMTS5 rs2830581 polymorphism. Huang et al.
ADAMTS5 rs2830581 polymorphism modified ADAMTS5 expression
To characterize the functional relevance of the ADAMTS5 rs2830581 polymorphism, we conducted a correlation analysis between the rs2830581 genotypes and the expression of ADAMTS5 protein assessed using IHC on the cancerous tissues collected in the study. The results showed that the genotypes with rs2830581 A alleles were significantly related to decreased ADAMTS5 expression in hepatocellular tumor tissues, compared with rs2830581-GG ( Fig. 1A ; P < 0.01). To analyze this correlation further, subjects were divided into three groups based on ADAMTS5 expression scores in the tumors, representing low, medium, and high expression of ADAMTS5. ADAMTS5 expression was found to be negatively related to the expression of the polymorphism (r ¼ À0.313; Supplementary Table S6; Fig. 1B) . Moreover, mRNA levels of ADAMTS5 in cancerous tissues with rs2830581-GA or -AA were significantly lower than in those with rs2830581-GG (P < 0.01; Fig. 1C ). Together, these results suggest that this polymorphism modulates the expression of ADAMTS5.
ADAMTS5 rs2830581 polymorphism correlated with microvessel density
From previous reports, it is known that ADAMTS5 expression is capable of regulating hepatocellular carcinoma angiogenesis (14) . Thus, we explored how expression of ADAMTS5 rs2830581 polymorphism affected MVD (Fig. 1D) . The data showed that rs2830581-GA or -AA had a higher frequency of MVD, compared with rs2830581-GG [OR (95% CI/P), 2.50 (1.98-3.16/1.65 Â 10 À14 ) for rs2830581-GA and 7.29 (5.09-10.43/2.33 Â 10 À27 ) for rs2830581-AA, respectively]. Moreover, these risk-associated genotypes increased the risk of portal vein tumor [PVT; OR ¼ 2.14 (1.65-2.79) and 5.74 (3.64-9.06) for rs2830581-GA and -AA, respectively; Fig. 1E ].
ADAMTS5 rs2830581 polymorphism modified hepatocellular carcinoma prognosis
To study the effects of ADAMTS5 rs2830581 polymorphism on the outcome of hepatocellular carcinoma patients, survival follow-up information of all hepatocellular carcinoma patients was analyzed. The association analysis between high-risk genotypes (namely, genotypes with rs2830581 A alleles; rs2830581-GA/AA) or low/no-risk genotypes (rs2830581-GG) and the pathologic characteristics of hepatocellular carcinoma were performed separately (Supplementary Table S7 ). A significant difference between genotypes among different AFB1 exposure levels, tumor size, tumor grade and TNM stage, and PVT and TP53M status, but not in age, gender, race, HBsAg, anti-HCV, or cirrhosis was observed. Results of the Kaplan-Meier survival analysis showed that ADAMTS5 polymorphism significantly correlated with shorter overall survival (OS) and recurrence-free survival (RFS) of hepatocellular carcinoma cases ( Fig. 2A and B) , particularly under conditions of high aflatoxin exposure (Fig. 2C-H) . From Cox regression analysis ( Table 3 ) we showed that the ADAMTS5 polymorphism is capable of affecting hepatocellular carcinoma prognosis (rs2830581-AA risk value, HR ¼ 3.57 for RFS and 2.18 for OS, respectively). Furthermore, some evidence of multiplicative interaction was found for rs2830581 polymorphism and AFB1 exposure (P interaction < 0.05). Taken together, these results indicated that this polymorphism is independent of other clinical covariates and suggested its potential as an independent prognostic factor for hepatocellular carcinoma.
ADAMTS5 rs2830581 polymorphism modified the effects of transcatheter arterial chemoembolization (TACE) treatment on hepatocellular carcinoma
The effect on patient survival in ADAMTS5 rs2830581 polymorphism was investigated to determine whether there was a correlation with effectiveness of a chosen therapy. Information from TACE-treated hepatocellular carcinoma patients who received curative resection treatment (Supplementary Table S8) was collected in accordance with the Chinese Manage Criteria of hepatocellular carcinoma (24) . Although TACE treatment improved hepatocellular carcinoma prognosis as a whole (Fig.  3A and B, Supplementary Fig. S1A and S1B), stratified analysis based on the different genotypes of ADAMTS5 rs2830581 revealed that TACE treatment had no effect on the RFS and OS of hepatocellular carcinoma patients with rs2830581-AA genotype ( Fig. 3C and D, Supplementary Fig. S1C and S1D ). Interestingly, patients with rs2830581-GA or -GG polymorphisms that received TACE treatment had a prolonged OS and RFS (Fig. 3E-H,  Supplementary Fig. S1E-S1H) . By using these with rs2830581-AA but not receiving TACE treatment as a reference, a joint statistical analysis between ADAMTS5 genotypes and TACE treatment on hepatocellular carcinoma prognosis was performed (Supplementary Fig. S2A-S2D) . The results indicated that hepatocellular carcinoma cases with rs2830581-GG would face a noticeably decreased risk of death and tumor reoccurrence under the conditions of TACE treatment (OS: HR ¼ 0.28, 95% CI, 0.22-0.36; RFS: HR ¼ 0.17, 95% CI, 0.12-0.24). Taken together, the data suggest that ADAMTS5 rs2830581 polymorphism could potentially modify the effects of TACE treatment and improve the prognosis of hepatocellular carcinoma patients.
Discussion
On the basis of a large-scale case-control study, we investigated the association between ADAMTS5 polymorphisms and the risk of hepatocellular carcinoma in a high AFB1 exposure area of Guangxi province. It was found that the genotypes of ADAMTS5 with rs2830581 A alleles had a substantial association with the increasing risk of hepatocellular carcinoma (OR, 2.37; 95% CI, 2.05-2.74). Interestingly, an interaction between genotype and environment was found for populations having the rs2830581 A alleles, and exposed to different levels of AFB1. This study represents the first report indicating the potential of ADAMTS5 polymorphisms as biomarkers and prognostic indicators of hepatocellular carcinoma. In addition, we report that these polymorphisms alter the effects of TACE treatment as well. ADMATS5 rs2830581 polymorphism correlated with ADAMTS5 expression and pathologic features of hepatocellular carcinoma (HCC). A, ADAMTS5 protein expression was evaluated using the IHC scores of IRS system according to the following formula: IRS ¼ SI Â PP, as described elsewhere. ADAMTS5 expression scores are shown as box plots, with horizontal lines representing the median, the bottom and the top of the boxes representing the 25th and 75th percentiles, respectively. We compared genotypes with rs2830581 A alleles (rs2830581-GA and rs2830581-AA) with rs2830581-GG using the Mann-Whitney U test. B, representative images show that different expression levels were observed in cancerous tissues from cases with different ADAMTS5 genotypes (scale bars: 50 mm). C, qRT-PCR analysis of ADAMTS5 mRNA level in hepatocellular carcinoma tumor tissues from 207 subjects. The relative expression of ADAMTS5 mRNA is shown as box plots, with horizontal lines representing the median, the bottom and the top of the boxes representing the 25th and 75th percentiles, respectively, and vertical bars representing the range of data. We compared the difference among group using the Mann-Whitney U test. Any outliers are marked with a circle and extreme cases are marked with an asterisk. D and E, the microvessel density (MVD) and percentage of portal vein tumor (PVT)-positive tumors in three groups with different genotypes of rs2830581 from 1,706 subjects. Data were analyzed using Pearson c 2 test. The association between hepatocellular carcinoma (HCC) prognosis and both AFB1 exposure and ADMATS5 rs2830581 polymorphism in 1,706 hepatocellular carcinoma patients. A and B, the genotypes with rs2830581 A alleles (rs2830581-GA and -AA) were found to have a poorer overall survival (OS) or tumor recurrence-free survival (RFS) than rs2830581-GG. C-H, the joint effects of AFB1 exposure and rs2830581 polymorphism further modified hepatocellular carcinoma prognosis. Cumulative hazard function was plotted by Kaplan-Meier's methodology, and P value was calculated with two-sided log-rank tests. MST, the median overall survival time; MRT, the median tumor recurrence-free survival time.
ADAMTS5 is well known for its role in cartilage biology (1, 25) , and that it is the major aggrecanase in mouse cartilage in an inflammation model of arthritis (26) . Previously, studies have suggested that ADAMTS5 may be involved in the development and progression of cancers affecting the breast, prostate, brain, colorectal tissue, and liver (10, 14, 16, (27) (28) (29) . Porter and colleagues (27) found that ADAMTS5 expression in breast cancer tissues was downregulated in cancerous tissues with respect to nonneoplastic mammary tissue, irrespective of the heterogeneity of the samples and the tumor type or grade. Kim and RomanGomez (10, 16) observed that the ADAMTS5 gene exhibited hypermethylation in colorectal cancer and T-cell acute lymphoblastic leukemia. Additional studies have indicated that it may be possible for this gene to suppress tumor growth and progress (9, 14, 16) . In contrast, other reports indicated that ADAMTS5 expression was upregulated in human glioblastoma compared with normal brain tissues and promoted glioma cell invasiveness in culture (28) . Together, the collected data indicate that ADAMTS5 may serve different functions in different cancer types. Thus, the role of ADAMTS5 in cancer, including hepatocellular carcinoma, needs to be further evaluated.
More than 1,000 SNPs have been reported in the ADAMTS5 gene, some of which were found in correlation with human disease (11, 13, 17, 18 ). In the current study, 74 known SNPs were analyzed because of their indicated involvement with the structure and expression of ADAMTS5, and potential involvement in hepatocellular carcinoma carcinogenesis (13) . Of the polymorphisms analyzed, only rs2830581 polymorphism (located in the 3 0 UTR of ADAMTS5) was found to be associated with increased hepatocellular carcinoma risk from first stage screening and second stage validation. Furthermore, this polymorphism was found in correlation with AFB1 exposure status in hepatocellular carcinoma patients. These data suggest this polymorphism may be an important genetic susceptibility factor in cancer risk. Coincidentally, a previous case-control study from Chongqing Region, a non-AFB1 exposure area in China, has shown that rs2830585 modifies hepatocellular carcinoma risk. Supplementary the aforementioned modifying role, the data indicated that the polymorphism affected hepatocellular carcinoma risk in the first-stage screening analysis, despite a lack of statistical significance. Therefore, the possibility that the genetic polymorphisms in ADAMTS5 influence hepatocellular carcinoma risk through an alternative pathway should not be ignored.
To explore the effect of ADAMTS5 rs2830581 polymorphism on AFB1-related hepatocellular carcinoma risk, expression of ADAMTS5 and the pathologic features of hepatocellular carcinoma were examined. It was found that this polymorphism was associated with the downregulation of ADAMTS5 expression, increasing MVD, tumor progression, dedifferentiation, and metastasis. A recent in vivo and in vitro study has shown that downregulation of this gene accelerates hepatocellular carcinoma angiogenesis and carcinogenesis by modifying VEGF expression (14) . The survival analysis further indicated that the rs2830581 polymorphism was associated with poor outcome of hepatocellular carcinoma patients, highlighting the potential roles of this polymorphism in predicting the prognosis of hepatocellular carcinoma induced by AFB1 exposure. Collectively, these results suggest that ADAMTS5 rs2830581 polymorphism could modulate the antitumorigenesis role of ADAMTS5, increasing AFB1-related hepatocellular carcinoma risk and shortening prognosis of this tumor.
Another important finding in this study was that ADAMTS5 rs2830581 polymorphism was found to modify the effects of TACE treatment on hepatocellular carcinoma patients. This is likely due to the downregulation of ADAMTS5 expression and increased MVD, an important control factor for TACE treatment.
In the current study, major strengths were its prospective twostage design, large sample size, and the panel of a relatively large number of systematically identified SNPs in ADAMTS5. The effects of possible confounders (including age, gender, nationality, and HBV and HCV infection status) were controlled with an individually matched design. In addition, AAA and TP53M was used to test this exposure and correlation because AAA is a stable biomarker reflecting long-term AFB1 exposure status, whereas TP53M is the characteristic genetic change resulting from AFB1 exposure, and higher frequency of this mutation predicts higher The different therapeutic value of TACE on hepatocellular carcinoma (HCC) cases in three groups with different genotypes of ADAMTS5 rs2830581 from 1,299 subjects. A and B, TACE treatment was found to improve overall survival (OS) or tumor recurrencefree survival (RFS). C-H, the effects of TACE treatment on hepatocellular carcinomas' OS and RFS within strata of ADAMTS5 rs2830581 genotypes. Cumulative hazard function was plotted by Kaplan-Meier's methodology, and P value was calculated with two-sided log-rank tests. MST, the median overall survival time; MRT, the median tumor recurrence-free survival time.
AFB1 exposure and higher hepatocellular carcinoma risk. In the current study, we found hepatocellular carcinoma cases had a higher serum AAA and more than 70% of them featured TP53M, which was similar to the data from other countries of South East Asia (30) .
However, there were several limitations to our study. First, because 74 SNPs were evaluated in the screening set, whereas only 4 were evaluated in the validation set, false-negative results were a considerable issue. In this study, the correction for multiple testing was done using the correlation matrix-based method, which takes into account the LD between SNPs (22). Second, potential selection bias might have occurred through the selection of hospital-based control subjects. Third, the increased risk with AFB1 exposure seen in this study was probably underestimated because liver disease itself may affect the metabolism of AFB1 and modify the levels of AFB1 adducts (2, 31) . Finally, although we analyzed the effects of the ADAMTS5 rs2830581 polymorphisms on the ADAMTS5 expression and MVD, we failed to accomplish more functional analysis. Thus, more functional analyses deserve elucidation based on large samples and a combination of genes and AFB1 exposure.
This study represents the first report describing genetic polymorphisms of ADAMTS5 and their association with AFB1-related hepatocellular carcinoma risk and prognosis. The findings provide an additional insight into the ADAMTS5 rs2830581 polymorphism as biologic determinants of hepatocellular carcinoma risk and prognosis related to AFB1 exposure. Interestingly, the effects of ADAMTS5 polymorphism on TACE therapy for hepatocellular carcinoma treatment indicated a positive association between the two. Understanding the different value in individual patients will allow more information counseling with regard to screening, prevention, treatment options, follow-up plans, and approaches for secondary prevention. Therefore, these findings, in combination with clinicopathologic information of hepatocellular carcinoma, could improve the identification of high-risk populations, especially from high AFB1 exposure areas.
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